Mammalian cells are commonly employed in screening assays to identify active compounds that could potentially affect the progression of different human diseases including retinitis pigmentosa (RP), a class of inherited diseases causing retinal degeneration with compromised vision. Using transcriptome analysis, we compared NIH3T3 cells expressing wildtype (WT) rod opsin with a retinal disease-causing single P23H mutation. Surprisingly, heterologous expression of WT opsin in NIH3T3 cells caused more than a 2-fold change in 783 out of 16,888 protein coding transcripts. The perturbed genes encoded extracellular matrix proteins, growth factors, cytoskeleton proteins, glycoproteins and metalloproteases involved in cell adhesion, morphology and migration. A different set of 347 transcripts was either up-or downregulated when the P23H mutant opsin was expressed suggesting an altered molecular perturbation compared to WT opsin. Transcriptome perturbations elicited by drug candidates aimed at mitigating the effects of the mutant protein revealed that different drugs targeted distinct molecular pathways that resulted in a similar phenotype selected by a cell-based high-throughput screen. Thus, transcriptome profiling can provide essential information about the therapeutic potential of a candidate drug to restore normal gene expression in pathological conditions.
Introduction
Small molecules are the mainstay of pharmacotherapeutics for the treatment of human diseases. Such agents often are easy to administer, well tolerated by patients, and relatively inexpensive. Nonetheless, complex diseases remain difficult to manage, and typically worsen with age. In infectious diseases or cancer, poly-pharmacology aimed at diverse and unrelated targets can effectively deal with the primary problem but often with adverse side effects. This risk can be acceptable for treating terminal diseases or chronic life-threatening infections but not for slowly progressive diseases that are not fatal or overly burdensome during a patient's normal lifespan. To minimize such drug side effects, recent approaches in systems biology can be used to characterize the molecular features of disease models used in both the early and later stages of drug development [1, 2] . Moreover, these technologies can be adapted to improve our understanding of the http://dx.doi.org/10.1016/j.phrs.2016. 10 .031 1043-6618/© 2016 Elsevier Ltd. All rights reserved.
pharmacology of a starting molecule with respect to its possible off-target effects and therapeutic potential.
Retinitis pigmentosa (RP) is a progressive retinal degenerative disease associated with mutations in more than 50 genes [3, 4] . Effective treatments of RP are unavailable, even though gene therapy [5, 6] and pharmacological intervention with valproic acid [7] [8] [9] [10] [11] are currently undergoing clinical trials. The rhodopsin pigment, comprised of the protein opsin bound to a vitamin A chromophore that is regenerated in the endoplasmic reticulum and outer segment disc membranes, is an essential component of rod photoreceptor cells due to its pivotal role in phototransduction and its abundance in the photosensitive outer segments [12] . Thus, it is not surprising that Rho encoding the rod opsin, is the most frequent causal gene among autosomal dominant (ad) RP patients [3, 13] . The P23H mutation, observed in 10% of adRP cases, is a representative Class II mutation that causes opsin misfolding due to its thermal instability [3, [13] [14] [15] [16] . Instability of P23H opsin leads to its progressive massive degradation in the rod photoreceptors of P23H knock-in mice [17, 18] . To rescue these photoreceptors, we hypothesized that improving P23H opsin stability could decrease photoreceptor cell death and improve vision. Alternatively, increasing the degradation of mutant opsin and leaving the WT rhodopsin allele to preserve visual function could be an equally viable therapeutic strategy for adRP. Thus, we developed and performed two sets of cell-based, small-molecule high-throughput screens (HTSs) to identify compounds that either improve the stability of the P23H opsin mutant or enhance its degradation [19] . Even though a valid photoreceptor cell line is unavailable, mammalian cells have been commonly used to study the biosynthesis of rhodopsin and to screen for drug candidates because the pre-ciliary biosynthesis of rhodopsin is generally shared by mammalian cells and rod photoreceptor cells [14, 20, 21] . In mammalian cell cultures, heterologously expressed WT opsin is located on the plasma membrane whereas P23H opsin accumulates in the endoplasmic reticulum (ER) due to its structural instability [14] [15] [16] [19] [20] [21] .
For drug discovery, lead compounds identified from HTS in cell models are then tested in an animal model that represents the genetic defect and exhibits pathological signs seen in the corresponding human disease. The challenge of developing drug candidates showing efficacy in both cell and animal models sometimes lies in the dramatic difference of the two model systems. To improve our success rate of drug development, we need a better understanding of our disease models and the lead compounds' mechanisms of action. Advances in microarray and next generation sequencing (NGS)-based transcriptome profiling (RNAseq) have already identified novel molecular pathways or key genes associated with the development of disease states in the mouse retina [22] [23] [24] [25] [26] [27] [28] [29] [30] . Although transcriptome studies have been applied to low-dose pharmacological treatments in disease models to evaluate drug efficacy and side effects [30] [31] [32] [33] [34] , RNA-seq studies have rarely been used in the early stages of drug discovery to characterize the cell models used for high throughput screening and to investigate a lead compound's mechanism of action [30, 35, 36] .
Here, using high-throughput RNA-seq technology, we profiled the transcriptomes of three stable cell lines expressing either opsin/green fluorescent protein (GFP), P23Hopsin/GFP or GFP alone, under different treatment conditions. This study addresses three questions related to drug discovery: (1) what are the general transcriptome changes in an established mammalian cell line due to heterologous expression of rod opsin; (2) what transcriptome changes arise from the expression of the P23H opsin mutant; and (3) what genes and associated molecular pathways are affected by treatment with active compounds selected from a HTS?
Materials and methods

Cells
NIH3T3 (WTopsin/GFP), NIH3T3 (P23Hopsin/GFP) and NIH3T3 (GFP) stable cell lines were generated by viral infection with pMiLRO, pMiLRO23 and pMXs-IG constructs, as previously published [19] . Mouse opsin or P23H opsin was co-expressed with GFP. When single clones were selected, no significant differences were observed between them with respect to cell shape, GFP fluorescence or localization of WT opsin (on the plasma membrane) or P23H opsin (in the ER) suggesting the defect of P23H opsin transport is not due to a clonal difference.
Immunostaining and fluorescence imaging
Immunostaining and fluorescence imaging followed published procedures [19] . Briefly, cells were seeded in a 384-well plate at 5000 cells/well on day 1. These cells were treated with active compounds or a DMSO control on day 2. Cells were fixed with 4% paraformaldehyde 24 h after treatment. Rod opsin was immunostained with 1D4 monoclonal anti-rhodopsin antibody [37] followed by secondary labeling with Cy3-conjugated goat anti-mouse antibody (Jackson Immuno Research, West Grove, PA, USA). Nuclei were stained with DAPI. Fluorescence images were captured with an Operetta High Content Imaging System (PerkinElmer, Waltham, MA, USA). Five images were taken from each well of the 384-well plate containing a total of 600-1000 cells. Three channels of fluorescence emission were used, Alexa488 (GFP), DAPI, and Cy3. Representative images of immunostained cells are shown in Fig. 1A-F. 
Image analysis
Only intact cell images were selected for analysis. The cytoplasm was defined by the GFP fluorescence of each cell with the cell boundary as the 0% line. Nuclei were visualized by DAPI fluorescence, and each nucleus, as defined by its edges, was assumed to comprise 50% of each cell. The membrane region was defined within 5% around the cell boundary, and the ER region was defined within 25-50% at the perinuclear region. Opsin staining on the plasma membrane was represented by the ratio of Cy3 intensity in the membrane region to that in the entire cell (MEM-total). Opsin staining in the ER region was denoted by the ratio of Cy3 intensity in the ER region to that in the entire cell (ER-total). MEM-total and ER-total were averaged from all the imaged intact cells in each well. Each condition was repeated in 3 or 8 wells, for treatments or controls, respectively. MEM-total and ER-total were then averaged from those biological repeats and presented as data points in Fig. 1G -N. Error bars were standard deviations from those biological repeats.
Identification of active compounds by HTS
Compound 1 (an isoquinoline-2(3H)-hexanamide) and compound 2 (4-(5-chlorothiophen-2-yl)furan-2(5H)-one) were selected by a cell-based HTS of small molecules from the University of Cincinnati 2.5 K Diversity Set of Small-Molecules Library [19] . To identify small molecular compounds which rescue the P23H opsin mutant from ER retention, we performed a HTS with a ␤-galactosidase fragment complementation assay as described in reference [19] . Briefly, two complementary subunits of beta-galactosidase were individually fused with a plasma membrane-anchored peptide, the PH domain of phospholipase C delta (PLC), and the mouse opsin P23H mutant, respectively. A U2OS stable cell line was generated that consistently expresses Immunofluorescence and image analysis of NIH3T3 cells expressing GFP and opsins. Panel A, only GFP was expressed; panel B, WT opsin and GFP were co-expressed; panels C-F, P23H opsin mutant and GFP were co-expressed; GFP, Cy3 labeling associated with 1D4 anti-rhodopsin antibodies and nuclei stained with DAPI are shown in green, yellow, and blue, respectively. Cells were treated with 0.05% DMSO in A-C; 5 M of compound 1 in D; 10 M of compound 2 in E; and 5 M compound 1 plus 10 M of compound 2 in F. Arrows in B-F indicate opsin (WT or P23H) staining in the ER region. Scale bar, 20 m. Quantification of opsin on the plasma membrane (G) and in the ER region (K) by image based analysis. Unlike WT opsin stained on the cell boundary, the P23H opsin mutant accumulated in the perinuclear region of NIH3T3 cells. Treatment with compound 1 reduced the perinuclear accumulation of P23H opsin, whereas treatment with compound 2 induced a significant amount of plasma membrane staining of P23H opsin. Co-treatment with both compounds 1 and 2 demonstrated a synergistic rescue of P23H opsin transport to the plasma membrane. For image analysis, the cytoplasm was defined by GFP fluorescence whereas the nucleus was defined by DAPI fluorescence. The MEM-total was calculated as the mean ratio of Cy3 intensity on the plasma membrane region to that in the entire cell. The ER-total was calculated as the mean ratio of Cy3 intensity in the perinuclear region to that in the entire cell. NIH3T3 cells expressing P23H or WT opsin were treated with 0.1% DMSO as controls (G and K). NIH3T3 cells expressing the P23H opsin were treated with compound 1 (H and L), compound 2 (I and M) or compound 2 with 5 M compound 1 (J and N); each compound was tested in 10 concentrations starting at 20 M and followed by 2-fold dilutions. Data points and error bars represent averages and standard deviations of biological replicates. these two fusion proteins. Due to its inherent instability, the P23H opsin fusion protein accumulates in the ER, whereas the PLC fusion protein remains anchored on the plasma membrane of these cells. Separation of the two fusion proteins led to a complete lack of beta-galactosidase activity. Upon treatment with an active compound that stabilizes P23H opsin folding and transport to the plasma membrane, two complementary beta-galactosidase subunits were colocalized on the plasma membrane resulting in a recovery of beta-galactosidase activity read by its luminescence. Using this cell-based assay in a 384-well format, we screened the University of Cincinnati 2.5 K Diversity Set of small-molecules library and identified four hit compounds. An immunostaining and high-content imaging assay then was used to identify lead compounds with true activity. Both compound 1 and compound 2 increased transport of the P23H opsin mutant to the plasma membrane, despite sharing little chemical or structural similarity.
Treatment of cell culture with active compounds
Each cell line was cultured at 37 • C with 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 units/mL penicillin, 100 g/mL streptomycin, and 2.92 g/mL l-glutamine (Hyclone). The three cell lines were cultured to the same passage to achieve 90% confluence in a 50 mm culture dish before subsequent treatment. Five cell assay conditions were used: (1) NIH3T3(GFP) cells were treated with 0.05% DMSO, denoted as Control; (2) NIH3T3(WTopsin/GFP) cells were treated with 0.05% DMSO, denoted as Opsin; (3) NIH3T3(P23Hopsin/GFP) cells were treated with 0.05% DMSO, denoted as P23H; (4) NIH3T3(P23Hopsin/GFP) cells were treated with 5 M of compound 1, denoted as T1; (5) NIH3T3(P23Hopsin/GFP) cells were treated with 10 M of compound 2, denoted as T2. Each treatment condition was replicated in three 50 mm dishes. After 24 h of each treatment, the medium was aspirated, and cells were washed with phosphate-buffered saline (PBS, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4, 137 mM NaCl, and 2.7 mM KCl) before being lysed.
RNA extraction
Cells were lysed with TRIzol (1 mL/dish, Thermo Fisher Scientific, Grand Island, NY, USA), and total RNA was extracted from each sample according to the TRIzol reagent manual [38, 39] . Extracted RNA samples were analyzed with a 2100 Bioanalyzer Nano chip (Agilent Technologies Genomics, Santa Clara, CA, USA) to assess total RNA quality (RIN: 10). RNA from each sample then was labeled and stored at −80 • C before RNA-seq analysis.
RNA-seq and data analyses
All transcript libraries were made with the TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA). The 100 base paired samples were run on 2 lanes of a Hiseq 2500 Sequencing system (Illumina) with Rapid mode running RTAv1.18.61 software. Illumina adapter trimming was performed with Trimmomatic v0.33. Quality control (QC) was analyzed with FastQCv0.11.2 software. Reads were processed in parallel by both qualitative and quantitative analyses with multiple types of software including Bowtie2 v2.2.1, TopHat2 v2.0.11, Samtools v0.1.19, and eXpress v1.3.1, as previously described in Ref. [40] using the GRCm38 assembly and ENSEMBL v78 annotation. Expression analyses were performed with R v3.11. Principal component analysis was conducted to validate the reproducibility of replication (Table 1) . TMM (trimmed mean of M-values) normalization was done with EdgeR v3.6.8 to normalize the count data in different samples that varied in depth. Differential expression (DE) was analyzed by Iimma v3.22.3 that employed the Iimma voom function for estimating dispersion [41] . For DE analysis, only transcripts wherein all replicates of any sample group were greater than 1 fragment per kilobase of transcript per million mapped reads (FPKM) were kept in the data set. FPKM values rather than count values were used to reduce length bias in transcript filtering. DE statistics were obtained by moderated t-test, Enhanced Bayes, and Benjamini-Hochberg calculations, yielding P values, F and B-statistics, and false discovery Table 1 The number of sequencing reads generated for each sample and their alignment statistics. The alignment statistics refer to the number and percentage of reads that align to the genome and to the annotation used in the analysis. Reads mapping to the genome assembly but not the annotation are from intergenic, intronic, or novel transcripts not present in the annotation.
Samples
Total Reads Assembly Annotation % Genome % Assembly rates (FDRs), respectively. The DE filter was set for transcripts with FPKM fold changes of more than 2 and an FDR of less than 5%. Hierarchical clustering heatmaps were generated by Affinity Propagation employing the APcluster package in R using the Z-score of normalized FPKM values.
Gene ontology and biological process pathway analyses
Gene ontology (GO) analysis was initially performed with DAVID Bioinformatics Resources 6.7 (The Database for Annotation, Visualization and Integrated Discovery, http://david.abcc.ncifcrf.gov/ home.jsp) [42, 43] . Functional Annotation Clustering was used only for the "Biological Processes" category at a GO level of 5 and greater. GO terms that had the lowest P values in each cluster as well as low FDR values were listed. The total number of genes included in all of the listed GO terms was considered to be 100%, and the number of genes in each GO term was calculated as a percentage in a pie chart for data visualization.
Reverse transcription and quantitative real-time polymerase chain reaction (qPCR)
RNA was extracted from cells and reverse transcribed into cDNA using the high capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA) following the manufacturer's protocol. These cDNA samples were used as templates for qPCR. The qPCRs were performed using CYBR Green Super Mix (Bio-Rad Laboratories, Hercules, CA, USA). A total of 2 ng of cDNA was added to 10 L of CYBR Green Super Mix, 8 L of purified H 2 O and 1 L of primers including forward and reverse primers at 10 M each. Each reaction therefore contained a 20 L solution in a single well of a 96-well PCR plate. We quantified 9 transcripts by qPCR using Gapdh as the control transcript. The 9 transcripts included: Txnip, Nqo1, Gstp1, Pfdn6, Itch, Dnajb14, Vdr, Clec16a, and Masp1. Specific bands of qPCR products were confirmed by DNA gel electrophoresis, stained with ethidium bromide and visualized by UV fluorescence. Primers for the 9 transcripts were:
Txnip forward: 5 -TGGTGAAGCAGGC-3 ; reverse: 5 -TGAAGTCGCAGGAGACAACC-3 . The fold change for each transcript was first normalized by Gapdh, and then compared to Control (NIH3T3 cells expressing GFP only). Fold changes were averaged from three biological replicates and error bars were from standard deviations of those replicates. P values comparing two conditions were calculated with the two-sample Student's t-test.
Results
To discover effective small molecular drugs for retinitis pigmentosa associated with the rhodopsin P23H mutation, we previously undertook a cell-based HTS to identify small molecules rescuing the P23H opsin from misfolding and ER retention, using a beta-galactosidase complementation assay [19] . Briefly, using the complemented beta-galactosidase activity as a reporter, the amount P23H opsin successfully transported to the plasma membrane was quantified by its luminescence read from a microplate reader. In 384-well plates, we screened the University of Cincinnati 2.5 K Diversity Set of small-molecule library and identified compound 1 and compound 2 that featured outstanding potency as well as efficacy. Compound 1 (an isoquinoline-2(3H)-hexanamide) showed its EC 50 at 3.1 M with an efficacy score of 87% whereas compound 2 ((4-(5-chlorothiophen-2-yl)furan-2(5H)-one)) had an EC 50 at 5.5 M with an efficacy score of 166%. Both activity scores were normalized to 100% as exhibited by the effect of treatment with 5 M 9-cis-retinal.
To confirm the activity of these two lead compounds for rescuing the transport of P23H opsin mutant from the ER to the plasma membrane, three stable NIH3T3 cell lines were generated for the immunostaining and high-content imaging assay [19] . GFP was expressed, either with the opsin protein or by itself, as a positive selection marker to help generate the stable cell lines. In agreement with reports describing other mammalian cell models [14, 21, [44] [45] [46] [47] [48] [49] , the WT opsin protein localized to the plasma membrane of NIH3T3 cells as demonstrated by the staining of cellular boundaries, whereas the P23H opsin mutant accumulated in the perinuclear region with little plasma membrane staining indicating its predominant retention in the endoplasmic reticulum (ER) (Fig. 1A-C) . This mislocalization was noted in all clones of stable cells, suggesting the defect of P23H opsin transport is due to its structural instability, rather than an artificial clonal difference. To quantitatively compare the cellular localization of the WT and P23H opsins, we undertook an image-based analysis to quantify the immunostaining of opsin on the plasma membrane versus that in the ER relative to the total opsin staining in each cell (MEMtotal versus ER-total, Fig. 1 ). For controls, quantitative analysis of 8 biological repeats, each calculated from images of 600-1000 cells, provided reliable baselines representing "normal" and "aberrant" conditions. In agreement with what was observed from the images in Fig. 1B and C, relative staining of WT opsin was significantly higher on the plasma membrane (MEM-total = 0.20, Fig. 1G ), and lower in the ER (ER-total = 0.27, Fig. 1K ), as compared to P23H opsin staining.
Two small molecular compounds were found from the HTS which rescued transport of P23H opsin from the ER to the plasma membrane. Treatment with compound 1 resulted in a reproducible redistribution of P23H opsin throughout the cell body (Fig. 1D) , with a dose-dependent increase in cell boundary staining (MEMtotal increased from 0.10 up to 0.14, EC 50 = 0.48 M, Fig. 1H ), but little change in the ER region (Fig. 1,L) . Comparably, treatment with compound 2 also increased the plasma membrane staining of P23H opsin (MEM-total increased from 0.10 to 0.16, EC 50 = 7.5 M, Fig. 1E and I) , whereas its perinuclear staining was reduced in a dose dependent manner (ER-total decreased from 0.36 to 0.31, EC 50 = 6.1 M, Fig. 1M ). Interestingly, co-treatment with both compounds produced a significant improvement of P23H opsin transport to the plasma membrane (MEM-total increased from 0.12 up to 0.20, EC 50 = 5.2 M, Fig. 1J ), which also dramatically reduced the perinuclear accumulation of the opsin mutant (ER-total decreased from 0.36 to 0.27, EC 50 = 8.1 M, Fig. 1N ). The differing cellular distribution of P23H opsin upon treatment with these two compounds and their synergic effect suggest that they utilize distinct cellular targets.
To understand the effect of heterologous expression of opsin or the P23H mutant and the molecular events altered by treatment with compounds 1 and 2, we profiled the transcriptomes of different sample groups. Principle component analysis showed the consistency between repeats of each sample group ( Fig. 2A and Table 1 ). Protein-coding transcripts with fold changes of more than 2 and a false discovery rate (FDR) less than 5% were collected in each DE profile of two cellular conditions. FPKM reads of Rho transcripts from NIH3T3 cells expressing WT opsin and NIH3T3 cells expressing the P23H opsin mutant were similar (Fig. 2B) , suggesting that the changes in transcripts between the two cell lines were not due to differential expression of the Rho transgenes.
Heterologous expression of opsin and its mutants in mammalian cells has been used extensively to study rhodopsin biochemistry and identify drug candidates [14, 20, 21, [44] [45] [46] [47] [48] . However, it is unknown whether expression of opsin produces a transcriptome change within the host cell line and if analysis of changes in the transcriptome could be used for validation of lead compounds from HTS. Here, a total of 783 out of 16,888 protein coding transcripts revealed differential expression in Opsin versus Control cell lines (Fig. 2C) . Notably, many of the perturbed genes are relevant to pathways involved in cell adhesion, morphology and migration and encode extracellular matrix proteins, growth factors, cytoskeleton proteins, glycoproteins or metalloproteases (Efemp1, Adamts1, Col8a1, Col11a1, Calhm2, Loxl4, Tgfbi, Jam3, Angptl2, Kitl, Gpnmb, Neo1, Dcn, Prl2c2 and Prl2c3) (Fig. 3A) . These changes in expression could represent a stress response due to the heterologous expression of opsin in NIH3T3 cells, which are fibroblasts that feature elevated expression of extracellular matrix proteins [35, 50, 51] . Among other significantly altered genes, some are involved in transcriptional regulation or RNA splicing (Zfp518a, Hnmph1, Sp140, Ankrd1 and Mef2c), and others participate in cellular responses to oxidative stress (Srxn1, Prdx5), protein glycosylation (Prmt1), and lipid transport (Vldlr). Their changes could be due to cellular adaptation required to support the biosynthesis of the opsin protein, a G protein-coupled receptor (GPCR). Alternatively, the DE profile of Opsin versus Control cells includes many genes containing cAMP responsive elements (CREs) [52] which could be regulated by the leaky activity of free opsin [53] [54] [55] coupled to endogenous G i/o protein signaling [7, 16, 56] . Such genes include but are not limited to Gsta4, Pcx, and Pdk4 involved in metabolic processes; Per1, Ppargc1a and Egfr1 that regulate gene transcription; the growth factor Prl2c2; the neurotransmitter Inhba; and Ppp1r15a involved in DNA repair (Table 2) . A more complete evaluation of biological processes affected by the expression of opsin in NIH3T3 cells is presented in Fig. 3B . P23H opsin revealed a transcriptome shift compared to WT opsin expressed in NIH3T3 cells. We identified 347 differentially expressed genes from the DE profile of P23H versus control, indicating that far fewer genes were affected by expression of the mutant opsin (Fig. 2C) . A total of 176 of these genes showed differential expression in both Opsin versus Control and P23H versus Control, and among these, 159 genes evidenced the same trend. These similar changes could result from common structural and biochemical properties shared by P23H opsin and WT opsin. GO analysis of these genes revealed a significant enrichment of genes involved in the vesicle transport pathway, such as Klc1, Stx16, Kif1c, Myo7a, Dlg4 and Lrp8 (Table 3) . Transcripts involved in metabolism, apoptosis, and transcription pathways were similarly changed in both DE profiles of Opsin versus Control and P23H versus Control.
To assess transcriptome differences between the disease and control models, we compared the DE profiles of P23H versus Opsin that identified 330 transcripts (Fig. 4A) . Among these transcripts, 271 were not seen in the DE profile of P23H versus Control, but did show up in the profile of Opsin versus Control. This result suggests that 84% of the transcripts that displayed differential expression in P23H versus Opsin are altered due to molecular perturbations induced by the expression of WT opsin but not P23H opsin. This result could be due to the significant reduction of folded P23H opsin protein as a result of its ER accumulation and its enhanced degradation in these NIH3T3 cells [19] . GO analysis showed significant enrichment in genes involved in cell adhesion (P value = 0.00004 and Benjamini = 0.06), including Col8a1, Col16a1, Col11a1, Cdh18, Cdh11a, Pcdhb1, Pcdhb17, Pcdhb21, Pcdh1, Alcam, Ncam, Fn1, and Jam3 (Fig. 4A, genes denoted in black) .
Apart from genes revealing the lost transcriptional perturbation by the P23H opsin mutant, there were 59 genes observed in DE profiles of both P23H versus Control and P23H versus Opsin, suggesting that these changes resulted from the aberrant properties of the P23H opsin mutant. These genes can be classified as participating in: (1) cell adhesion (Thbs1, Napsa, Vcan); (2) cell differentiation (Vdr, Eya1, Sprr1a, Nrp, Egln3); (3) membrane protein biosynthesis (Galnt13, Fam69b); (4) lipid transport (Apol10b); and (5) glycoprotein degradation (Lyz2) (Fig. 4A, genes denoted in  red) . Activation of the ER-associated degradation (ERAD) pathway has been reported in the P23H knock-in mouse model [57] and in mammalian cell models transfected with P23H opsin [21, 58] . However, genes related to ERAD did not change significantly in NIH3T3 cells upon continuous expression of either WT opsin or the P23H opsin mutant (Table 4 ). Molecular chaperones including calnexin, BIP/Grp78 and GRP94 were reported to directly associate with P23H opsin in cell cultures [49, 59] , and EDEM1 was reported to be responsible for the initiation of the ERAD of P23H opsin [60] . Here we observed a slight upregulation of molecular chaperones including Hspa5 (Bip), Hsp90b1 (Grp94), Edem2 and Calr (encoding calreticulin) but not Edem1 or Canx (encoding calnexin) in cells expressing P23H opsin compared to those expressing WT opsin. These data suggest that the instability of P23H opsin could have moderately induced molecular chaperones to maintain protein homeostasis (Fig. 4B) . However, no significant changes of other ERAD genes (Atf4, Atf6, Ern1(Ire1), Eif2ak3, Eif2a or Ddit (Chop)) were observed in DE profiles of P23H versus Opsin (Fig. 4B) , suggesting that NIH3T3 cells can be intrinsically adapted to protein Representative transcripts that showed DE in P23H versus Opsin but not in P23H versus Control are in black print, suggesting loss-of-opsin-properties in the P23H opsin mutant. Those that showed DE in both P23H versus Opsin and P23H versus Control are indicated in red, suggesting gain-of-abnormal-properties in the P23H opsin. B. FPKM reads of transcripts in the endoplasmic reticulum associated protein degradation (ERAD) pathway of the three stable cell lines. The results suggest no significant activation of this pathway due to expression of WT or P23H opsin. Each sample group had three biological replicates.
Table 4
Mean FPKM reads of transcripts involved in the endoplasmic reticulum associated degradation (ERAD) pathway of NIH3T3 cells expressing GFP (Control), Opsin/GFP (Opsin), or P23Hopsin/GFP (P23H). Mean FPKM reads were calculated from 3 biological repeats. misfolding. Moreover, no significant induction of caspase expression was seen in DE profiles of P23H versus Opsin. Due to differences between immortalized NIH3T3 cells and mouse photoreceptors [61, 62] , transcriptome changes in a cell line should be interpreted with caution and cannot be directly correlated with the molecular events that occur in a mouse bearing the P23H mutation. Rather, to understand the molecular events involved in photoreceptor death, transcriptomes derived from mouse retina at an early age before photoreceptor death occurs should be compared between wild type and heterozygous P23H knock-in animals. But here, our goal of comparing transcriptomes between these cell lines was to obtain information pertinent to drug discovery through early stage analyses of molecular events following various treatments. Thus, we identified two active compounds through a cell-based, small molecule HTS, both of which rescued the transport of P23H opsin back from the ER to the plasma membrane. Each compound produced a different distribution pattern for the P23H opsin and cotreatment with both resulted in a synergistic rescue of P23H opsin homeostasis (Fig. 1) . These results suggest that these two active compounds target different cellular pathways which culminate in a similar cellular effect. Such affected pathways can be revealed by cellular transcriptome changes that are sensitive to perturbations of cellular conditions. To delineate the molecular events initiated by each of these compounds, we compared the DE profiles of T1 versus P23H and T2 versus P23H (Fig. 5) . The DE profile of T1 versus P23H recorded 2715 changed transcripts, whereas that of T2 versus P23H showed no significant changes. These transcriptome changes were captured 24 h after treatments when rescue of P23H opsin transport was first observed (Fig. 1D and E) . Therefore, this finding suggests that the rescue of P23H opsin transport by T1 could primarily result from transcriptional regulation, whereas compound 2 could directly target the P23H opsin protein or other proteins that improve the folding or transport of the opsin mutant without directly affecting transcription.
The transcriptional impact of treatment with compound 1 (T1) was profound, causing a greater than 16% change in the transcriptome (Fig. 5A) . Due to the large number of transcripts affected by T1, these transcripts were initially grouped as either up-or downregulated before the GO analysis. Biological processes affected by T1 then were classified (Fig. 5C ). Among the enriched pathways, genes involved in vesicle-mediated transport (2%), regulation of microtubule cytoskeleton organization (2%), and regulation of protein modifications (3%) correlated with the improved P23H opsin transport observed by immunostaining (compare Fig. 1D with C) . Notably, 117 genes were reversed in the DE profile of T1 versus P23H compared to the DE profile of P23H versus Opsin (Fig. 5B) , suggesting these affected genes by P23H opsin were somehow "corrected" by T1. Correlating with the observation that T1 partially rescued the transport of the P23H opsin, changes of these transcripts by T1 could involve pathways either causing or being effected by the rescued P23H opsin transport. These genes were manually classified according to their biological functions documented in the Gene Cards Human Gene Database (http://www.genecards.org) (Fig. 5D) . The top 25 up-and down-regulated transcripts with known functions are listed next to their classifications. The most relevant biological processes to P23H opsin biosynthesis include, but are not limited to those regulating cytoskeleton dynamics, vesicle transport, protein folding and ERAD, as well as a response to oxidative stress. Among transcripts responding to oxidative stress, Gstp1 and Nqo1 were down-regulated in P23H versus Opsin and up-regulated in T1 versus P23H. These genes protect cells from reactive oxygen species generated during protein biosynthesis by transferring thiol groups for disulfide bonds [63] . Up-regulation of Gstp1 and Nqo1 could represent an elevated response to reactive oxygen species that is frequently correlated with protein misfolding. Notably, molecular chaperones Dnajb14 and Pfdn6 (prefoldin6), both involved in protein folding and ERAD, were down-regulated in P23H and reversed by T1. Expression of Dnajb14 was reported to accelerate the degradation of misfolded membrane proteins such as the cystic fibrosis transmembrane conductance regulator 508 (CFTR 508) [64] . Prefoldins were previously reported to prevent ubiquitinated-protein aggregation under ER-stress [65] [66] [67] . Upregulation of these two molecular chaperones can be correlated with the improved homeostasis of P23H opsin in NIH3T3 cells. The same trend of changes was confirmed by qPCR ( Fig. 6 ; Table 5 ). Collectively, this study identified candidate genes for further investigation to attain a better understanding of the molecular targets of T1 and its affected pathways that can improve the homeostasis of misfolded opsin mutants.
In contrast to the profound transcriptome shift by T1, the lack of transcriptome alterations by treatment with compound 2 (T2) suggests that, in addition to transcriptome analysis, other systems biology techniques such as proteomics [68] are also needed for compound-target profiling. Recent work on a truncated mutant of CFTR ( F508) clearly demonstrates that a global interactome remodeling occurs to CFTR interacting partners which are crucial for membrane localization [69] .
Discussion
We have identified two small molecular compounds that rescued the transport of a disease-causing P23H opsin mutant in a mammalian stable cell line. Though the synergistic effect of these two compounds supports their distinctive molecular targets, it is still unclear as to which molecular pathways were affected by their treatment. In attempting to answer this question, we report several observations after analyzing the transcriptomes of stable cell lines expressing WT or P23H opsin that we had used for discovering drugs for the treatment of retinitis pigmentosa [19] . First, we have shown that cell lines used for drug discovery should be profiled to appreciate their advantages and limitations as disease models. Second, we demonstrated that techniques associated with approaches in systems biology such as transcriptome profiling can be developed as a standard procedure for compound profiling at early stages of drug discovery to guide further investigation of lead compounds' mechanisms of action. Whereas treatment with compound 1 reversed 117 transcripts that were "abnormally" expressed due to aberrant P23H opsin, treatment with compound 2 did not affect the transcriptome of cells expressing the P23H opsin. This finding confirmed that these two compounds have distinct mech- Table 5 Fold change of transcripts comparing NIH3T3 cells expressing the P23H opsin and GFP that was treated with compound 1 and those treated with DMSO (T1 versus P23H). anisms of action, even though treatment with each compound resulted in a partially rescued transport of P23H opsin. Transcriptome analysis already is used routinely to study molecular events during both the development of the normal retina and the onset and progression of degenerative retinal diseases. It will not be too long before this technique is broadly employed during drug discovery for treatment of such diseases. RNA-seq-based transcriptome analysis has been used to examine the efficacy of potential drugs for diabetic retinopathy in a mouse model [30] . A recent study used microarray analysis to examine the pathways changed by small molecular agents that could prevent staurosporine-induced apoptosis of NIH3T3 cells [35] . The transcriptome analysis of control and treated cells identified changes in gene expression affected by apoptotic conditions that could be reversed by treatment with drugs used in the screen.
Modern genetic profiling can enhance systems pharmacology in the endeavor to improve the design of drugs and their testing in models of complex human diseases. First, genetic profiling can provide a global assessment of the alterations in signaling systems caused by disease. Any perturbation of a native state, even resulting from a single mutation, can alter many cellular networks to induce a new steady-state that then is manifestd as a disease phenotype. For example, removal of the retina-specific leucine zipper gene, Nrl [70] alters hundreds of transcripts that change the photoreceptor population [28, 29, 71] . Similarly, mice with a genetic A/J background exhibit variations in hundreds of transcripts compared to C57Bl/6J WT mice, driving complex alterations associated with cone photoreceptor cell degeneration [72] . Modern genetic profiling also can determine how well a therapy returns an abnormal gene expression landscape toward more normal conditions. In this study, we showed that treatment with compound 1 regulated transcripts involved in multiple pathways related to membrane protein biosynthesis and transport. These effects can be viewed as desirable activities of compound 1. In contrast, transcripts affected by compound 1 that relate to cell cycle and apoptosis could be counted as risk factors that should be tested in animal models for potential side effects. Connections between various intra-and inter-cellular pathways must be considered when evaluating drug safety and efficacy and even the duration of a successful therapy. Thus, the initial specificity of a drug does not guarantee its long-term effectiveness or safety. Rather, genetic profiling can assess the molecular consequences in multiple cell-types associated with a particular drug treatment and thereby improve ultimate drug design [73] .
The transcriptome changes observed in NIH3T3 cells with rod opsin expression could be specific to this cell line and have little direct correlation with free rod opsin signaling in photoreceptor cells in vivo [37, 58, 59] . However, the DE profile of Opsin versus Control is a transcriptional measure of the molecular properties induced by WT opsin in NIH3T3 cells that can be compared to the DE profile of P23H versus Control (Table 3) . This finding could link the cause, namely the P23H single mutation, with its consequences, i.e. ER retention of P23H opsin in these cells. Notably, even though NIH3T3 cells lack the photoreceptor cell's tertiary outer segment ciliary structure, the pre-ciliary biosynthesis of opsin is similar in both types of cells. The defect of P23H opsin transport is due to its structural instability and ER retention, a pre-ciliary defect. Therefore, the transcriptome difference between the two stable cell lines expressing the WT or P23H opsin, in parallel to the transcriptome difference between WT or P23H knock-in mouse models, provides an essential set of data to understand the advantages and limitations of cells used for drug discovery.
In short, uncommonly used in small molecular screening, we employed NGS to evaluate a simple cellular system as a disease model for drug discovery. This strategy can then be tailored to identify novel and effective compounds or combinations of compounds eventually applicable to the treatment of complex human diseases as recently reported in animal models [74] .
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